ClinicalTrials.gg
Not yet recruitingNCT05411237Updated Jan 23, 2026

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

A Phase 3 interventional study of Pegylated liposomal doxorubicin and Paclitaxel in Kaposi Sarcoma, HIV-1-infection and AIDS-related Kaposi Sarcoma, sponsored by AIDS Malignancy Consortium. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Primary conditionAIDS-related Kaposi sarcomaRegistry: Sarcoma, KaposiReclassifiedWhy we changed it
Registry
Sarcoma, Kaposi — the first condition term the registry derived for this study.
ClinicalTrials.gg
AIDS-related Kaposi sarcoma
Why
  1. The study's listed conditions name AIDS-related Kaposi sarcoma, a narrower term within Sarcoma, Kaposi.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AIDS Malignancy Consortium · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium — 2 open to participants now, 2 under way, 1 of them phase 3. AIDS-related Kaposi sarcoma · AIDS Malignancy Consortium.

Started
2026
with 1 other
Phase 3
Only one
of the 12
Registered
10th of 12
by date

Among the 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium, this one is one of 2 that started in 2026, is the only one in phase 3, and was the 10th registered.

AIDS-related Kaposi sarcoma

43 studies on the registry are indexed under AIDS-related Kaposi sarcoma; 2 are open to participants now.

Browse AIDS-related Kaposi sarcoma studies →

Open to participants now

2 of the 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1 AIDS-related Kaposi sarcoma study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium, or all of them as a file.
02

Study summary

This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.

03

Conditions studied

  • Kaposi Sarcoma
  • HIV-1-infection
  • AIDS-related Kaposi Sarcoma

Browse trials for

Keywords

  • Paclitaxel
  • Pegylated liposomal doxorubicin
  • AIDS associated Kaposi Sarcoma
  • Human Immunodeficiency Virus
  • HIV-related Kaposi Sarcoma
04

In context

AIDS-related Kaposi sarcoma Reclassified

43 studies on the registry are indexed under AIDS-related Kaposi sarcoma; 2 are open to participants now.

This study's planned enrollment of 130 is above the median of 30 across 28 interventional studies indexed under AIDS-related Kaposi sarcoma.

Browse AIDS-related Kaposi sarcoma studies →

Lead sponsor

AIDS Malignancy Consortium is the lead sponsor of 61 studies on the registry; 9 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.

Compared within AIDS-related Kaposi sarcoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sarcoma, Kaposi. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -1 infection.
  2. confirmed KS at any time prior to study entry, confirmed by an AIDS Consortium (AMC)-certified pathologist.
  3. Current stage T1 KS (irrespective of prior treatment with antiretroviral therapy (ART) OR

    Stage T0 KS that has progressed or not responded after a minimum of 12 weeks of treatment with ART. Participants with T0 KS must have either:

    • 20 or more skin and/or oral KS lesions, and/or
    • any number of lesions on exposed body areas that have an adverse effect on quality of life (e.g., stigmatization).
  4. Men and women ≥ 18 years. Because no dosing or adverse event data are currently available on the use of PTX or PLD for AIDS-KS in persons \<18 years of age, children are excluded from this study
  5. performance status ≥ 60 ( ≤ 2).
  6. Echocardiogram or Multiple gated acquisition scanning () showing an ejection fraction ≥ 50%.
  7. Ability and willingness of participant or legal guardian to provide .
  8. Participants may be ART-naïve or ART-experienced but must be able to receive an ART regimen considered likely to result in HIV suppression.
  9. Measurable cutaneous KS, defined as follows:

    • When available, a minimum of five bi-dimensionally measurable KS cutaneous marker lesions.
    • If fewer than five bi-dimensionally measurable marker lesions are available, the total surface area of the marker lesion(s) must be ≥ 700mm2.
  10. The following laboratory values obtained within 14 days prior to study entry:

    • ≥ 1000 cells/mm3.
    • ≥ 8 g/dL (may be achieved with transfusion if clinically indicated, in the opinion of the investigator).
    • count ≥ 75,000/mm3.
    • , AST, Alkaline phosphatase \< 5 × (ULN).
    • Total : ≤ 1.5 × ULN, unless the participant is receiving an antiretroviral drug known to be associated with increased bilirubin, in which case the direct fraction should be ≤ 2 x the ULN.
    • Creatinine \< institutional ULN OR estimated (GFR) ≥ 30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
  11. Women of , defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months), must have a negative pregnancy test done within 24 hours of initiating the protocol-specified chemotherapy medication.
  12. Participants must agree to use two reliable forms of simultaneously while receiving study protocol-specified medication and for 6 months after stopping the medication.
  13. Adequate venous access.
  14. No prior chemotherapy or use of systemic cytotoxic therapy agents.
  15. Participant is able to understand and willing to sign a written informed consent document.

Exclusion criteria

Exclusion Criteria:

  1. Current acute, chronic, or recurrent infections that are serious, in the opinion of the site investigator, for which the participant has not completed at least 14 days of therapy before study entry and/or is not clinically stable.
  2. Serious illness necessitating hospitalization/systemic treatment within 14 days prior to study entry
  3. Breastfeeding or pregnant women are excluded because of potential risks of cytotoxic chemotherapy to an unborn child or infant.
  4. Known history of congestive heart failure and/or systolic \< 50%.
  5. Prior radiotherapy to KS indicator lesions
  6. Prior or current immunotherapy
  7. Any immunomodulator, vaccine, , other vaccine within 30 days prior to study entry, excluding vaccines against COVID-19/SARS-CoV-2, which are permitted.
  8. Known allergy/ to the study drug or its formulation
  9. Any condition, including the presence of laboratory abnormalities, which in the opinion of the responsible investigator places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
  10. use at doses above those given for replacement therapy for adrenal insufficiency within the last 30 days prior to study entry.
  11. Patients with psychiatric illness and/or social circumstances that would limit compliance with study requirements.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Active comparator
    Pegylated Liposomal Doxorubicin

    Participants will receive a single intravenous dose of PLD 20 mg/m2 once every 3 weeks for a total of 18 weeks.

    Drug: Pegylated liposomal doxorubicin

  • Active comparator
    Paclitaxel

    Participants will receive a single intravenous dose of PTX 100 mg/m2 once every 3 weeks for a total of 18 weeks.

    Drug: Paclitaxel

Interventions

07

What researchers measure

Primary outcomes

  1. Progression Free Survival at 48 weeks

    Progression free survival (PFS) is defined as the length of time from enrollment into the study until disease progression or death. Disease progression will be assessed using the Kaposi Sarcoma Response Evaluation Criteria. Progressive disease is defined as: 1) 25% increase in the sum of perpendicular diameters of the indicator lesions; 2) 25% increase in the total number of KS lesions or the appearance of 5 new lesions; OR 3) 25% increase in the number of raised lesions

    Time frame: 48 weeks

Secondary outcomes

  1. Frequency and severity of adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 in participants receiving PLD or PTX.

    The frequency of adverse events that occur in patients receiving PLD will be compared with the frequency of adverse events in patients receiving PTX

    Time frame: 96 weeks

  2. Objective response rate for AIDS-related KS in patients receiving PLD and PTX

    The objective response rate is defined as the sum of the number of complete and partial responses in patients receiving PLD or PTX.

    Time frame: 96 weeks

  3. Duration of Response in patients receiving PLD and PTX

    Response duration is defined as the time from first documentation of complete or partial response as measured by KS response criteria to the documentation of first progression of disease as measured by KS response criteria

    Time frame: 96 weeks

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Chapola JC, Kleber SL, Krown SE, Painschab M. Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin. Cost Eff Resour Alloc. 2025 Nov 24;23(1):78. doi: 10.1186/s12962-025-00677-x. PubMed 41286911 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2022
First posted
Jun 9, 2022
StartEst.
Sep 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2030
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05411237
Lead sponsor
AIDS Malignancy Consortium
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Sep 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2030 (estimated)
Last update
Jan 23, 2026

Study contacts

Margaret Borok- Williams, MD
Contact
mborok@mweb.co.zw
+263 (242) 791-631
Susan Krown, MD
study chair · AIDS Malignancy Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal doxorubicin · Paclitaxel

Start the discussion